作者
Filipe A Moura, Valeria N Figueiredo, Bruna SBS Teles, Meyrianne A Barbosa, Lara R Pereira, Ana PR Costa, Luiz Sergio F Carvalho, Riobaldo MR Cintra, Osório LR Almeida, Jose C Quinaglia e Silva, Wilson Nadruz Junior, Andrei C Sposito, Brasilia Heart Study
发表日期
2015/11/1
期刊
Atherosclerosis
卷号
243
期号
1
页码范围
124-130
出版商
Elsevier
简介
Objective
Chronic dysglycemia was recently identified as a predictor for adverse outcomes in patients with ST-elevation myocardial infarction (STEMI) treated by percutaneous coronary intervention. Data for non-diabetic patients who underwent thrombolysis is scarce. In this context, we aimed to study the effect of HbA1c on cardiovascular outcome after STEMI.
Methods
A prospective cohort of 326 non-diabetic STEMI individuals was used for the analyses. We measured plasma glucose, hemoglobin A1c [HbA1c], lipid profile, C-reactive protein (CRP), and nitrate/nitrite (NOx) upon admission and five days after STEMI (D5). Flow-mediated dilation (FMD) was performed 30 days after STEMI. During clinical follow-up, we assessed patients for incident diabetes (progression to HbA1c ≥ 6.5%) and major adverse cardiac events (MACE), defined as a composite of fatal and non-fatal MI, sudden cardiac death, and angina …
学术搜索中的文章
FA Moura, VN Figueiredo, BSBS Teles, MA Barbosa… - Atherosclerosis, 2015